Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3484356 drug-drug interaction and food effect study in healthy females
NCT04840888Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of imlunestrant (6 cohorts), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity at 96 hours, Time of Maximum Observed Concentration at 96 hours and 1 more. Started Apr 2021; status: completed.
02
Drugs
imlunestrant
Beyond the preview
Go deeper on NCT04840888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840888.